WallStSmart

Becton Dickinson and Company (BDX)vsLeMaitre Vascular Inc (LMAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 8468% more annual revenue ($22.48B vs $262.43M). LMAT leads profitability with a 25.0% profit margin vs 4.2%. BDX appears more attractively valued with a PEG of 1.11. LMAT earns a higher WallStSmart Score of 62/100 (C+).

BDX

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 5.5Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.49

LMAT

Buy

62

out of 100

Grade: C+

Growth: 7.3Profit: 8.5Value: 4.0Quality: 8.5
Piotroski: 4/9Altman Z: 3.16
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+11.1%)

Margin of Safety

+11.1%

Fair Value

$203.14

Current Price

$177.85

$25.29 discount

UndervaluedFair: $203.14Overvalued
LMATSignificantly Overvalued (-55.5%)

Margin of Safety

-55.5%

Fair Value

$56.44

Current Price

$80.59

$24.15 premium

UndervaluedFair: $56.44Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX1 strengths · Avg: 8.0/10
Price/BookValuation
2.0x8/10

Reasonable price relative to book value

LMAT4 strengths · Avg: 8.8/10
Altman Z-ScoreHealth
3.1610/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
25.0%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
29.0%8/10

Strong operational efficiency at 29.0%

EPS GrowthGrowth
22.6%8/10

Earnings expanding 22.6% YoY

Areas to Watch

BDX4 concerns · Avg: 3.0/10
P/E RatioValuation
31.2x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
3.9%3/10

ROE of 3.9% — below average capital efficiency

Profit MarginProfitability
4.2%3/10

4.2% margin — thin

EPS GrowthGrowth
-31.4%2/10

Earnings declined 31.4%

LMAT3 concerns · Avg: 3.7/10
PEG RatioValuation
2.114/10

Expensive relative to growth rate

P/E RatioValuation
27.8x4/10

Moderate valuation

Market CapQuality
$1.82B3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bull Case : LMAT

The strongest argument for LMAT centers on Altman Z-Score, Profit Margin, Operating Margin. Profitability is solid with margins at 25.0% and operating margin at 29.0%.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin. Thin 4.2% margins leave little buffer for downturns.

Bear Case : LMAT

The primary concerns for LMAT are PEG Ratio, P/E Ratio, Market Cap.

Key Dynamics to Monitor

BDX profiles as a value stock while LMAT is a mature play — different risk/reward profiles.

LMAT carries more volatility with a beta of 0.49 — expect wider price swings.

LMAT is growing revenue faster at 9.6% — sustainability is the question.

BDX generates stronger free cash flow (509M), providing more financial flexibility.

Bottom Line

LMAT scores higher overall (62/100 vs 52/100), backed by strong 25.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

LeMaitre Vascular Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.

Want to dig deeper into these stocks?